{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:48:55Z","timestamp":1794440935524,"version":"4.9.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Preclinical data suggest a rationale for combining CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 inhibitor. This phase 1b study evaluated lower-intensity CPX-351 combined with venetoclax in adults with acute myeloid leukemia (AML) considered unfit\/ineligible for intensive chemotherapy. In a dose-exploration phase using a 3+3 design, patients received stepwise dosing of CPX-351 IV on days 1 and 3 plus venetoclax 400\u00a0mg orally on days 2 to 21 per cycle to determine the recommended phase 2 dose (RP2D) for this combination. During the expansion phase, additional patients received CPX-351 plus venetoclax at the identified RP2D. The primary end points were the RP2D and safety of CPX-351 combined with venetoclax. Secondary end points included preliminary efficacy and pharmacokinetics. Overall, 35 patients were enrolled in the study. A RP2D of CPX-351 30 units\/m2 (daunorubicin 13.2\u00a0mg\/m2 and cytarabine 30\u00a0mg\/m2) plus venetoclax 400\u00a0mg was established. The safety profile of the combination was consistent with the known safety profiles of CPX-351 and venetoclax. Complete remission (CR)\/CR with incomplete hematologic recovery (CRi) was achieved by 17 of 35 patients (49%), all after cycle 1; of these, 14 were negative for measurable residual disease. CR was achieved by 1 of 8 patients (13%) with a mutation in TP53, and CR\/CRi was achieved by 15 of 26 patients (58%) with wild-type TP53. This study highlights that lower-intensity therapy of CPX-351 plus venetoclax as induction therapy provides a well-tolerated treatment option in adults with\u00a0AML deemed unfit for intensive chemotherapy. This trial was registered at www.ClinicalTrials.gov as #NCT04038437.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013687","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:33:36Z","timestamp":1729197216000},"page":"6248-6256","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"first","affiliation":[{"name":"1Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3129-9047","authenticated-orcid":false,"given":"Praneeth","family":"Baratam","sequence":"additional","affiliation":[{"name":"3Hematology\/Oncology Division, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Stuart","sequence":"additional","affiliation":[{"name":"3Hematology\/Oncology Division, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-8245","authenticated-orcid":false,"given":"Eric S.","family":"Winer","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"6Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"7Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Chakravarthy","sequence":"additional","affiliation":[{"name":"7Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Menno","sequence":"additional","affiliation":[{"name":"6Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Cheung","sequence":"additional","affiliation":[{"name":"7Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-6449","authenticated-orcid":false,"given":"Tara L.","family":"Lin","sequence":"additional","affiliation":[{"name":"8Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"12","key":"2024122319302559500_bib1","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3390\/cancers14122843","article-title":"CPX-351: an old scheme with a new formulation in the treatment of high-risk AML","volume":"14","author":"Molica","year":"2022","journal-title":"Cancers"},{"issue":"26","key":"2024122319302559500_bib2","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024122319302559500_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"2024122319302559500_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024122319302559500_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024122319302559500_bib6","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024122319302559500_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-134300","article-title":"Interim analysis of the phase 1b\/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction\/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed\/refractory AML [abstract]","volume":"136","author":"Lachowiez","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2024122319302559500_bib8","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024122319302559500_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"2024122319302559500_bib10","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024122319302559500_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A\u00a0phase Ib\/II study of ivosidenib with venetoclax\u00a0\u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2024122319302559500_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"2024122319302559500_bib13","unstructured":"Guidance for Industry: Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment. U.S. Department of Health and Human Services, Food and Drug Administration Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. 2022. Accessed 2 September 2024. https:\/\/www.fda.gov\/media\/162362\/download."},{"key":"2024122319302559500_bib14","doi-asserted-by":"crossref","first-page":"2040620720986646","DOI":"10.1177\/2040620720986646","article-title":"Venetoclax-containing regimens in acute myeloid leukemia","volume":"12","author":"Aldoss","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"suppl 1","key":"2024122319302559500_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-134832","article-title":"Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study [abstract]","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024122319302559500_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"2024122319302559500_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2024122319302559500_bib18","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024122319302559500_bib19","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1182\/blood-2022-171011","article-title":"Updated results of CPX-351 in combination with gemtuzumab ozogamicin (GO) in relapsed refractory (R\/R) acute myeloid leukemia (AML) and post-hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (HR-MDS) [abstract]","volume":"140","author":"Senapati","year":"2022","journal-title":"Blood"},{"issue":"16 suppl","key":"2024122319302559500_bib20","article-title":"V-FAST master trial: preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia [abstract]","volume":"40","author":"McCloskey","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024122319302559500_bib21","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"16 suppl","key":"2024122319302559500_bib22","article-title":"In\u00a0vitro cytotoxicity of CPX-351 plus venetoclax compared with hypomethylating agents or cytarabine plus venetoclax [abstract]","volume":"80","author":"Gupta","year":"2020","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2024122319302559500_bib23","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood-2023-182111","article-title":"Population pharmacokinetic-pharmacodynamic modeling of neutrophil and platelet count for lower-intensity therapy of CPX-351 combined with venetoclax in acute myeloid leukemia [abstract]","volume":"142","author":"Liang","year":"2023","journal-title":"Blood"},{"key":"2024122319302559500_bib24","article-title":"Prescribing information","author":"VENCLEXTA","year":"2022","journal-title":"AbbVie Inc"},{"issue":"2","key":"2024122319302559500_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"20","key":"2024122319302559500_bib26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024122319302559500_bib27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024122319302559500_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","article-title":"A\u00a0phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias","volume":"84","author":"Lin","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2024122319302559500_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jcph.1366","article-title":"Population pharmacokinetics and exposure-response analyses for CPX-351 in patients with hematologic malignancies","volume":"59","author":"Wang","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"suppl 1","key":"2024122319302559500_bib30","first-page":"5086","article-title":"Bone marrow cellularity and recovery of blood counts after venetoclax and azacitidine in elderly acute myeloid leukemia patients unfit for induction chemotherapy [abstract]","volume":"130","author":"Dugan","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024122319302559500_bib31","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.3324\/haematol.2017.182642","article-title":"Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm","volume":"103","author":"Walter","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024122319302559500_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2019-124500","article-title":"Genetic characteristics and outcomes by mutation status in a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia (AML) [abstract]","volume":"134","author":"Lindsley","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024122319302559500_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024122319302559500_bib34","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2021-150199","article-title":"CPX-351 for acute myeloid leukaemia: real world results are comparable to trial outcomes and exceeds them in non-adverse risk patients - a multicentre experience from West Midlands Hospitals on Behalf of West Midlands Research Consortium (WMRC) UK [abstract]","volume":"138","author":"Murthy","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024122319302559500_bib35","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood.2022016678","article-title":"Safety and efficacy of CPX-351 in younger patients (&lt;60 years old) with secondary acute myeloid leukemia","volume":"141","author":"Przespolewski","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024122319302559500_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2021-145947","article-title":"Comparing outcomes between liposomal daunorubicin\/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia [abstract]","volume":"138","author":"Grenet","year":"2021","journal-title":"Blood"},{"key":"2024122319302559500_bib37","author":"Todisco","year":"13-16  2024"},{"issue":"10","key":"2024122319302559500_bib38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","volume":"10","author":"Guolo","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024122319302559500_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2024122319302559500_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-142891","article-title":"Treatment with CPX-351 induces deep responses and TP53 mutation clearance in patients with t-AML and AML MRC, including younger patients and those with pre-existing MPNs: a real-world experience [abstract]","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2024122319302559500_bib41","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/bloodadvances.2021005859","article-title":"TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms","volume":"6","author":"Schimmer","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2024122319302559500_bib42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.21.01548","article-title":"Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses","volume":"40","author":"Norsworthy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024122319302559500_bib43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/hematology.2019000006","article-title":"Minimal residual disease and stem cell transplantation outcomes","volume":"2019","author":"Cloos","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2024122319302559500_bib44","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024122319302559500_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024122319302559500_bib46","first-page":"1326","article-title":"CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK","volume":"205","author":"Mehta","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"2024122319302559500_bib47","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clml.2023.07.003","article-title":"Real-world experience with CPX-351 treatment for acute myeloid leukemia in England: an analysis from the National Cancer Registration and Analysis Service","volume":"23","author":"Legg","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2024122319302559500_bib48","doi-asserted-by":"crossref","first-page":"e438662","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6248\/2346973\/blooda_adv-2024-013687-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6248\/2346973\/blooda_adv-2024-013687-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T19:30:39Z","timestamp":1734982239000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/24\/6248\/518219\/Lower-intensity-CPX-351-plus-venetoclax-induction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":48,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013687","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}